Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers

Cancer Letters(2025)10.1016/j.canlet.2025.217975Source: DataRank Database

Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers is a research paper published in Cancer Letters (2025). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

3 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.86)OA: closedTopics (43)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (18)

Joy Awosika ORCID,Cecilia Monge,Kelley Coffman ORCID,Changqing Xie ORCID,Nebojša Skorupan ORCID

Live enrichment

PubMed:40789510 OpenAlex:https://openalex.org/W4413107172

National Cancer Institute

Grant: ZIA BC 011345

Intramural NIH HHS

Grant: Z99 CA999999

Intramural NIH HHS

Grant: ZIA BC011343

U.S. Department of Health and Human Services

Foundation for the National Institutes of Health

National Institutes of Health

FWCI

1.86

Citation Percentile

0.9%

Citation Trend

2025

2026

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S0304383525005452?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383525005452?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.canlet.2025.217975

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40789510

Fields of Study

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersGut microbiota and health

MeSH Terms

TadalafilGastrointestinal MicrobiomeNivolumabAdministration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedPancreatic NeoplasmsVancomycinColorectal NeoplasmsTumor Microenvironment

Keywords

MedicineNivolumabHepatocellular carcinomaColorectal cancerInternal medicineClinical endpointGastroenterologyAdverse effectGut floraOncologyCancerImmunologyImmunotherapyClinical trialImmunomodulationNatural killer T cellsRegulatory T cellsTumor MicroenvironmentMyeloid-derived Suppressor CellsLiver MetastasesTumor-associated MacrophagesGut MicrobiomeBile Acid Metabolism

Sustainable Development Goals

SDG 0: Good health and well-being

Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers

FAIR Checklist

Authors (18)

Funding (6 grants)

Impact

Open Access

Topics